BTMD biote (BTMD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001819253
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
41
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about BTMD
Insiders, 180 days
+$202.2K net bought
1 buyer
biote insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, biote Corp. insiders bought a net $202.2K of stock across 36 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Aug 10, 2026.
- The trade is 6.7% of the 239,744 shares held after it.
- No other insider bought within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman Beer Marc D bought about $24.8K of BTMD on Aug 11, 2026; 41 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Mar 17, 2025.
- The trade is 51.8% of the 223,744 shares held after it.
- No other insider bought within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman Beer Marc D bought about $177.4K of BTMD on Aug 10, 2026, the largest insider purchase at the company since 2025; 41 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 6, 2025.
- +20.1% median (+20.1% mean) 90-day return after 2 previous buys.
- The trade is 0.3% of the 4,622,748 shares held after it.
- 2 other insiders bought within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Barrera Richard R bought about $39.1K of BTMD on May 7, 2025; 2 other insiders bought within 30 days and 41 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 21, 2025.
- The trade is 9.5% of the 4,611,071 shares held after it.
- 2 other insiders bought within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Barrera Richard R bought about $1.4M of BTMD on May 6, 2025; 2 other insiders bought within 30 days and 41 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Apr 7, 2025.
- +23.7% median (+18.5% mean) 90-day return after 6 previous buys.
- The trade is 0.0% of the 4,175,034 shares held after it.
- 3 other insiders bought within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RB Management GP LLC bought about $6.4K of BTMD on Apr 30, 2025; 3 other insiders bought within 30 days and 41 funds added in the latest 13F quarter.36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$202.2K over 180 days
+$202.2K over 90 days
more than 81% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
41 funds bought in last quarter
below 56% of Pharma & Biotech
Revenue
-2.5% year over year
below 59% of Pharma & Biotech
Margin
14.1% net margin
more than 84% of Pharma & Biotech
Buybacks
$5.9M repurchased, FY to 2026-06-30
below 78% of Pharma & Biotech
Short interest
6.6% of the float short (float per yahoo 2026-10-26) · 10.6 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BTMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-59.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BTMD: institutional holders (13F)
13F holdings, latest reported quarter
4,548,127 sh
$8.6M
2,065,482 sh
$3.9M
1,102,753 sh
$2.1M
436,088 sh
$824.2K
431,962 sh
$816.1K
Congress trades in BTMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BTMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BTMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$66.2K position · as of 2026-06-30
0.0%
Applied Finance IVS US SMID ETF
$6.9K position · as of 2026-06-30
0.0%
Clearwater Select Equity Fund
$101.3K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$187.9K position · as of 2026-06-30
0.0%
Clearwater Select Equity Fund
$29.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $202.2K bought by insiders over 180 days, 41 funds added last quarter. Each figure is a federal filing, dated the day it went public.
BTMD financials
Revenue growth
-2.5%
XBRL, annual
Net margin
14.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$183.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BTMD
| FY Dec 2025 | $192.2M |
| FY Dec 2024 | $197.2M |
| FY Dec 2023 | $185.4M |
| FY Dec 2022 | $165.0M |
| FY Dec 2021 | n/a |
| Jun 2026 | $44.2M |
| Mar 2026 | $44.9M |
| Dec 2025 | $46.4M |
| Sep 2025 | $48.0M |
| Jun 2025 | $48.9M |
| Mar 2025 | $49.0M |
| Dec 2024 | $49.8M |
| Sep 2024 | $51.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+3.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BTMD
| FY Dec 2025 | +14.1% |
| FY Dec 2024 | +1.6% |
| FY Dec 2023 | +1.8% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -14.8% |
| Mar 2026 | +5.1% |
| Dec 2025 | +4.2% |
| Sep 2025 | +17.1% |
| Jun 2025 | +6.5% |
| Mar 2025 | +28.0% |
| Dec 2024 | +7.4% |
| Sep 2024 | +20.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$19.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BTMD
| FY Dec 2025 | $30.2M |
| FY Dec 2024 | $38.8M |
| FY Dec 2023 | $26.5M |
| FY Dec 2022 | -$9.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$3.7M |
| Mar 2026 | $3.5M |
| Dec 2025 | $6.5M |
| Sep 2025 | $13.6M |
| Jun 2025 | $5.3M |
| Mar 2025 | $4.8M |
| Dec 2024 | $10.7M |
| Sep 2024 | $14.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity BTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 8.96x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.20x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt BTMD
| FY Dec 2025 | 0.34x |
| FY Dec 2024 | 0.42x |
| FY Dec 2023 | 0.24x |
| FY Dec 2022 | -0.08x |
| FY Dec 2021 | 0.91x |
| Jun 2026 | 0.20x |
| Mar 2026 | 0.32x |
| Dec 2025 | 0.34x |
| Sep 2025 | 0.39x |
| Jun 2025 | 0.40x |
| Mar 2025 | 0.42x |
| Dec 2024 | 0.42x |
| Sep 2024 | 0.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity BTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +535.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+5.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BTMD
| FY Dec 2025 | +23.5% |
| FY Dec 2024 | +2.3% |
| FY Dec 2023 | +2.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +40.8% |
| Jun 2026 | +5.7% |
| Mar 2026 | +14.7% |
| Dec 2025 | +23.5% |
| Sep 2025 | +27.1% |
| Jun 2025 | +31.7% |
| Mar 2025 | +14.8% |
| Dec 2024 | +2.3% |
| Sep 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+33.2%
operating income after a 31.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital BTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -80.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | +33.2% |
| Mar 2026 | +552.2% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+23.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BTMD
| FY Dec 2025 | +53.3% |
| FY Dec 2024 | +31.0% |
| FY Dec 2023 | +25.4% |
| FY Dec 2022 | -93.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | +23.4% |
| Mar 2026 | +42.8% |
| Dec 2025 | +53.3% |
| Sep 2025 | +57.4% |
| Jun 2025 | +70.2% |
| Mar 2025 | +29.3% |
| Dec 2024 | +31.0% |
| Sep 2024 | +38.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
10.73x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BTMD
| FY Dec 2025 | 3.47x |
| FY Dec 2024 | 56.18x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 17.18x |
| Mar 2026 | 3.07x |
| Dec 2025 | 3.47x |
| Sep 2025 | 3.75x |
| Jun 2025 | 4.42x |
| Mar 2025 | 5.55x |
| Dec 2024 | 56.18x |
| Sep 2024 | 17.44x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value BTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield BTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -88%, PEG needs growth
PEG, trailing BTMD
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.03x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $192.2M | $197.2M | $185.4M | $165.0M |
| Operating income | $35.6M | $31.6M | $28.7M | -$60.7M |
| Net income | $27.0M | $3.2M | $3.3M | -$969.0K |
| EPS (diluted) | 0.74 | 0.09 | 0.13 | -0.12 |
| Operating cash flow | $35.2M | $45.2M | $26.9M | -$9.2M |
| Cash | $24.1M | $39.3M | $89.0M | $79.2M |
| Long-term debt | $95.8M | $101.2M | $106.6M | $112.1M |
| Buybacks | $3.4M | $5.6M | n/a | n/a |
| Dividends paid | $1.7M | $4.7M | $8.7M | $12.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
BTMD Stock Sonar score 6/7 axes
Find similar shapesCompareBTMD ranks highest on profitability (85th percentile) and financial health (81st), and lowest on growth (41st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BTMD filings, in plain words
Are biote insiders buying or selling BTMD?
In the 180 days to 2026-10-28, biote insiders were net buyers, a net $202.2K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, biote insiders were net buyers of BTMD, a net $202.2K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
